The Week In... Pharma (29-06/03/07)
  • Posted on: 03/07/2020
  • Category: Industry

The Week In... Pharma (29-06/03/07)

Celltrion Healthcare gets positive CHMP opinion for additional Remsima SC indications, the NHS agrees a deal for a new cystic fibrosis drug, Gilead release an open letter on remdesivir pricing, and Cancer Research UK calls on the Scottish government to urgently restart cancer trials.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

Open letter from Gilead on remdesivir pricing for COVID-19

Daniel O’Day, Chairman & Chief Executive Officer of Gilead Sciences has released an open letter on remdesivir pricing for COVID-19.

Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis triple

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug.

Celltrion gets positive CHMP opinion for additional five indications for Remsima SC

The positive opinion recommends adding marketing authorization for Remsima SC for use in the treatment of five indications – inflammatory bowel disease (IBD), Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.

CR UK calls on Scottish gov to 'urgently' restart cancer trials

Cancer Research UK is urging Scotland’s government and health service providers to restart existing clinical trials for cancer as quickly as possible, following a 95% drop in new patients entering trials among the pandemic.

Mexico consulting with China, Oxford and AstraZeneca on coronavirus vaccine trials

Mexico is in talks with the Chinese government and private Chinese laboratories, as well as the University of Oxford and company AstraZeneca about running trials for experimental COVID-19 vaccines, a senior Mexican official said on Monday.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.